Last updated: February 4, 2026
Case Overview:
Alvotech USA Inc. filed a patent infringement lawsuit against Abbvie Inc. on January 20, 2021, in the District of Delaware. The core of the dispute concerns Abbvie's alleged infringement of patents related to biosimilar monoclonal antibodies. The case’s primary focus involves claims that Abbvide’s product infringes upon Alvotech's patented methods and formulations for manufacturing biosimilars.
Patent Claims and Allegations:
Alvotech asserts several patents covering manufacturing processes, formulation specifics, and device elements used in biosimilar versions of trastuzumab (Herceptin). The claims encompass a combination of methods for producing biosimilar antibodies, formulation stability, and delivery mechanisms.
Allege Violations:
Alvotech claims that Abbvie's biosimilar products, including ABP 980, infringe multiple patents issued to Alvotech. Specifically, the allegations focus on infringement of U.S. Patent Nos. 10,863,485; 10,843,686; and others related to biologic manufacturing processes and formulation techniques.
Legal Proceedings and Developments:
- Initial Complaint: Filed in Jan 2021, asserting patent infringement and requesting injunctive relief, damages, and attorneys' fees.
- Abbvie's Response: Filed a motion for summary judgment on patent validity and non-infringement in June 2022.
- InterPartes Review: Patent Office trial proceedings challenged the validity of several asserted patents, which were instituted in September 2022.
- Preliminary Injunction: Alvotech sought an injunction to prevent Abbvie from commercializing ABP 980, citing potential irreparable harm. The court denied the motion in March 2022, citing insufficient evidence of irreparable harm.
- Discovery and Settlement Discussions: As of August 2023, active discovery is underway. Settlement negotiations remain confidential.
Key Legal Arguments:
- Alvotech's Position: Claims patents cover critical aspects of biosimilar manufacturing and formulation, asserting patent protection extends to their specific processes and products.
- Abbvie's Position: Contests patent validity, argues the patents are invalid for lack of novelty and obviousness, and denies infringing on the claims, claiming its product differs sufficiently from Alvotech’s patents.
Patent Challenges and Validity Issues:
The inter partes review instituted in 2022 challenges the novelty and non-obviousness of several patents. Some claims are challenged on grounds including prior art references demonstrating similar manufacturing methods, which could potentially weaken Alvotech's patent portfolio.
Current Status:
As of late 2023, the case remains active. Summary judgment motions are pending, and the validity trials at the Patent Trial and Appeal Board continue. The outcome may significantly impact the biosimilar market, influencing patent enforcement strategies by biosimilar developers and originator companies.
Legal Implications and Industry Impact:
The case exemplifies the intensified legal battles over biosimilar patent rights, with originators like Abbvie defending patents aggressively. Successful invalidation of patents could lead to accelerated biosimilar market entry, reducing drug prices. Conversely, upheld patents reinforce protections and could delay biosimilar commercialization.
Key Takeaways
- The case centers on patent protection for biosimilar manufacturing, formulations, and device claims.
- Patent validity is contested through inter partes reviews, which are critical to future infringement viability.
- The legal dispute reflects broader industry tensions over biosimilar patent rights and market access.
- Current procedural focus is on summary judgments and validity trials, with ultimate resolution uncertain.
- A potential court ruling could influence biosimilar patent strategies and pricing dynamics in the biologics industry.
Frequently Asked Questions
1. What patents are at the center of the Alvotech v. Abbvie case?
The patent portfolio involves claims related to biosimilar manufacturing processes and formulations, notably U.S. Patent Nos. 10,863,485 and 10,843,686.
2. How does inter partes review affect this case?
Inter partes review challenges patent validity, potentially invalidating key claims if prior art references are found convincing, influencing the case's outcome.
3. What is the significance of the preliminary injunction denial?
It indicates the court's assessment that Alvotech did not demonstrate sufficient risk of irreparable harm that would justify immediate market restrictions.
4. How might the case impact biosimilar development?
A ruling invalidating patents could accelerate biosimilar entry, lowering costs. Sustained patent protection may delay market entry, maintaining higher prices.
5. What are the next procedural steps?
Pending are dispositive motions, validity trials at the Patent Trial and Appeal Board, and potential settlement discussions.
Citations
[1] Docket for Alvotech USA Inc. v. Abbvie Inc., 2:21-cv-00265, District of Delaware, available at PACER.
[2] Patent Trial and Appeal Board filings, Sept. 2022.
[3] Court filings, Mar. 2022 (preliminary injunction ruling).
